Moreover, the ZHER2:342 Affibody conjugated with N-[2-(4-18F-fluorobenzamido)ethyl]maleimide has demonstrated specificity in evaluating HER2 expression in vivo and in breast cancer metastasis models (20, 21). Here, ERBB2 is linked to breast carcinoma.